Teduglutide Peptide

The core mechanism of action of teduglutide peptide is to specifically bind to GLP-2 receptors in enteral tissues, activate a series of downstream signaling pathways, and ultimately promote the growth and repair of the intestinal mucosa and enhance its absorptive function. This process strictly follows the logic of "receptor binding – signal activation – effector response" and acts specifically in intestinal tissues, demonstrating clear target selectivity.

First, the targeted binding of it is highly specific. GLP-2 receptors are mainly distributed in enteroendocrine cells, subepithelial myofibroblasts, and enteric neurons in the submucosal and myenteric plexuses.

This distribution pattern restricts the action of the product primarily to the enteral mucosa and related tissues, minimizing significant effects on other organs. Gattex peptide exhibits binding affinity to GLP-2 receptors comparable to that of endogenous GLP-2 and can competitively occupy these receptors. Owing to its longer half-life, it sustains receptor occupancy and signaling activation, providing long-acting effects-one of its key therapeutic advantages over native GLP-2.

Second, downstream signal transduction following receptor activation is critical for the pharmacological effects of gattex peptide.

Upon binding to GLP-2 receptors, it activates receptor-coupled G proteins (predominantly Gαs proteins), which in turn activate adenylate cyclase (AC), leading to elevated intracellular cyclic adenosine monophosphate (cAMP) levels. As a second messenger, cAMP further activates protein kinase A (PKA), initiating a cascade of downstream signaling events. Activation of this pathway directly regulates the growth, proliferation, and differentiation of intestinal epithelial cells, while stimulating the release of various growth factors to support intestinal mucosal repair and growth.

During signal transduction, gattex promotes the local release of mediators including insulin-like growth factor-1 (IGF-1), keratinocyte growth factor (KGF), and nitric oxide (NO) via activated PKA signaling.

Among these, IGF-1 and KGF are key growth factors for enteral mucosal growth: IGF-1 stimulates intestinal epithelial cell proliferation, inhibits apoptosis, and accelerates the repair of mucosal injury; KGF acts primarily on basal intestinal epithelial cells to promote their proliferation and differentiation, increasing mucosal thickness. NO mainly participates in regulating intestinal blood circulation, improving blood supply to intestinal tissues to provide sufficient nutrients and oxygen for mucosal growth, while inhibiting intestinal smooth muscle contraction, slowing intestinal transit, prolonging the retention of nutrients in the intestine, and improving absorption efficiency.

Through GLP-2 receptor activation and downstream signaling, teduglutide peptide exerts three core physiological effects: promoting enteral mucosal growth, enhancing intestinal nutrient and water absorption, and regulating gastrointestinal function. These effects act synergistically to improve intestinal function, making it particularly suitable for the treatment of short bowel syndrome. Its physiological actions also extend to immunomodulation and inflammation control, further supporting intestinal health.

The first core physiological effect is the promotion of enteral mucosal growth and repair, the most pivotal action of the product. By activating downstream signaling pathways and releasing relevant growth factors, it significantly increases intestinal villus height and crypt depth, expanding the surface area of the intestinal mucosa. Both preclinical and clinical studies confirm that following gattex treatment, patients exhibit markedly increased villus height, deepened crypts, and enhanced mucosal thickness, which directly expand the absorptive surface for nutrients and improve intestinal absorption.

The second core physiological effect is enhanced intestinal absorption of nutrients and water. It achieves this through multiple pathways: on the one hand, the expanded intestinal mucosal surface directly increases absorptive sites for nutrients, improving the absorption of carbohydrates, fats, proteins, and other nutrients; on the other hand, it regulates the expression of nutrient transporters in intestinal epithelial cells, promoting the synthesis and activation of transporters for glucose, amino acids, fatty acids, and others, accelerating the translocation of nutrients from the intestinal lumen into enterocytes and further boosting absorption efficiency. Additionally, it enhances enteral water absorption, reducing fluid loss and relieving diarrhea, a common symptom in short bowel syndrome patients.

The third core physiological effect is the regulation of gastrointestinal function and reduction of gastrointestinal irritation, creating a favorable environment for nutrient absorption. The product inhibits gastric acid secretion, reducing acid-induced irritation to the intestinal mucosa, while protecting the intestinal mucosal barrier, decreasing the absorption of intestinal toxins, and lowering the risk of intestinal inflammation. Endogenous GLP-2 naturally inhibits gastric acid secretion and increases intestinal and portal blood flow, functions inherited and prolonged by gattex as its analogue. Furthermore, gattex slows intestinal motility, prolonging nutrient residence time in the intestine to allow more complete absorption.

In addition, the physiological effects of gattex peptide extend to immunomodulation and inflammation control. The intestine is the body's largest immune organ, and intestinal mucosal integrity is closely linked to immune function. By promoting mucosal repair and maintaining barrier integrity, teduglutide peptide reduces the invasion of pathogens and toxins, lowering enteral inflammation risk. It also modulates the intestinal mucosal immune system, promoting the release of anti-inflammatory factors and inhibiting pro-inflammatory cytokine expression, alleviating intestinal inflammatory responses.

Clinical studies show that although C-reactive protein levels may transiently and moderately increase during gattex treatment, long-term therapy results in no clinically relevant elevation from baseline, with no abnormal laboratory parameters or clinical symptoms, indicating favorable safety and regulatory effects on intestinal inflammation.